You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 20, 2025

Deciphera Pharms Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for DECIPHERA PHARMS

DECIPHERA PHARMS has two approved drugs.

There are forty-two US patents protecting DECIPHERA PHARMS drugs.

There are one hundred and sixty-three patent family members on DECIPHERA PHARMS drugs in twenty-nine countries.

Summary for Deciphera Pharms
International Patents:163
US Patents:42
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Deciphera Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes 11,911,370 ⤷  Try for Free Y ⤷  Try for Free
Deciphera Pharms ROMVIMZA vimseltinib CAPSULE;ORAL 219304-001 Feb 14, 2025 RX Yes No ⤷  Try for Free ⤷  Try for Free
Deciphera Pharms ROMVIMZA vimseltinib CAPSULE;ORAL 219304-002 Feb 14, 2025 RX Yes No 9,181,223 ⤷  Try for Free Y Y ⤷  Try for Free
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes 12,059,411 ⤷  Try for Free ⤷  Try for Free
Deciphera Pharms ROMVIMZA vimseltinib CAPSULE;ORAL 219304-001 Feb 14, 2025 RX Yes No 9,181,223 ⤷  Try for Free Y Y ⤷  Try for Free
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes 11,266,635 ⤷  Try for Free ⤷  Try for Free
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes 11,395,818 ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Deciphera Pharms – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Deciphera Pharmaceuticals has emerged as a notable player, carving out a niche in the development of kinase inhibitor treatments for cancer. This comprehensive analysis delves into Deciphera's market position, strengths, and strategic insights, offering a detailed look at how the company stands in the competitive landscape of oncology-focused pharmaceuticals.

The Deciphera Difference: Specialization in Kinase Inhibitors

Deciphera Pharmaceuticals has positioned itself as a specialist in the development of kinase inhibitors, a class of drugs that has shown significant promise in cancer treatment. This focus has allowed the company to build deep expertise in a critical area of oncology research.

QINLOCK: A Breakthrough in GIST Treatment

At the forefront of Deciphera's product portfolio is QINLOCK (ripretinib), a groundbreaking treatment for gastrointestinal stromal tumors (GIST). QINLOCK's success in treating fourth-line GIST has been a game-changer for patients with limited options.

"QINLOCK has shown remarkable potential in treating gastrointestinal stromal tumors (GIST). Its expansion into key European markets highlights the drug's growing impact and acceptance."[3]

Pipeline Potential: Vimseltinib and DCC-3116

Beyond QINLOCK, Deciphera's pipeline includes promising candidates like vimseltinib and DCC-3116. These drugs represent the company's commitment to expanding its therapeutic reach and addressing unmet medical needs in oncology.

Market Position: A Rising Star in Oncology

Deciphera's market position is characterized by its rapid growth from a research-focused entity to a commercial-stage biopharmaceutical company. This transition has been marked by several key factors:

Revenue Growth and Market Capitalization

As of December 31, 2023, Deciphera achieved a revenue growth rate of approximately 32.88%[10]. While this growth is significant, the company's market capitalization of about $2.2 billion[1] places it in a position where it still has room for expansion compared to larger pharmaceutical giants.

Global Expansion Efforts

Deciphera's strategic focus on expanding into European markets with QINLOCK demonstrates its ambition to become a global player in oncology treatments. This international expansion is crucial for long-term growth and market penetration.

Strengths and Competitive Advantages

Innovative Drug Development Platform

Deciphera's switch-control kinase inhibitor platform is a key strength, enabling the company to develop novel treatments with potentially higher efficacy and fewer side effects.

Strong Focus on Unmet Medical Needs

By targeting areas like GIST and tenosynovial giant cell tumor (TGCT), Deciphera addresses significant unmet needs in the oncology space, potentially leading to less competition and higher market demand.

Experienced Leadership Team

The company boasts a leadership team with extensive experience in pharmaceutical development. CEO Michael D. Taylor, for instance, brings over 25 years of experience in the biopharmaceutical sector[2].

Strategic Insights: Navigating the Competitive Landscape

Leveraging Partnerships and Collaborations

Deciphera's strategy includes forming strategic partnerships to enhance its R&D capabilities and market reach. The recent acquisition by Ono Pharmaceutical for $2.4 billion[1] is a testament to the company's value and potential for growth.

Diversification of Pipeline

While maintaining a focus on kinase inhibitors, Deciphera is diversifying its pipeline to include treatments for various types of cancer, reducing reliance on a single product or indication.

Emphasis on Personalized Medicine

The company's approach aligns well with the growing trend of personalized medicine in oncology, potentially positioning it at the forefront of tailored cancer treatments.

Challenges and Opportunities in the Market

Competitive Pressure

The oncology market is highly competitive, with numerous large pharmaceutical companies investing heavily in cancer research. Deciphera must continue to innovate to maintain its market position.

Regulatory Hurdles

As with all pharmaceutical companies, navigating the complex regulatory landscape for drug approvals remains a significant challenge and opportunity for Deciphera.

Market Expansion

While Deciphera has made strides in expanding globally, there's still significant potential for growth in international markets, particularly in emerging economies with growing healthcare sectors.

Financial Health and Future Projections

Solid Cash Position

With a cash position of $352 million as of early 2024[6], Deciphera has a runway extending into the second half of 2026, providing stability for ongoing research and development efforts.

Revenue Projections

The company expects QINLOCK and Vimseltinib to reach over $1 billion in peak global revenue[6], indicating significant growth potential in the coming years.

Research and Development Focus

Advancing Clinical Trials

Deciphera's commitment to advancing its clinical pipeline is evident in its ongoing trials, including the INSIGHT Phase 3 study for QINLOCK in second-line GIST patients[3].

Exploring New Indications

The company is actively exploring new indications for its existing drugs, such as the planned Phase 2 study for Vimseltinib in chronic graft-versus-host disease (GVHD)[6].

Marketing and Sales Strategy

Targeted Approach

Deciphera's marketing strategy focuses on educating healthcare providers about the benefits of its treatments, particularly in specialized areas like GIST and TGCT.

Digital and Social Media Presence

The company leverages digital platforms and social media to engage with patients, healthcare providers, and investors, enhancing its brand visibility in the pharmaceutical space.

Environmental, Social, and Governance (ESG) Initiatives

Commitment to Sustainability

Deciphera's 2022 ESG report highlights the company's dedication to environmental stewardship and social responsibility, factors increasingly important to investors and stakeholders[7].

Patient-Centric Approach

The company's PATHS values (Patients, Accountability, Transparency, Honesty and Integrity, and Stewardship) underscore its commitment to putting patients at the center of its operations[7].

Future Outlook and Potential Growth Areas

Expansion of Indications

Deciphera's future growth may come from expanding the indications for its existing drugs and bringing new candidates through the pipeline.

Potential for Mergers and Acquisitions

Given its recent acquisition by Ono Pharmaceutical, Deciphera may leverage this new relationship to expand its research capabilities and market presence further.

Technological Advancements

Incorporating AI and machine learning in drug discovery could significantly enhance Deciphera's R&D efficiency, potentially reducing the time and cost of bringing new drugs to market.

Key Takeaways

  • Deciphera Pharmaceuticals has established a strong position in the kinase inhibitor market, with QINLOCK as its flagship product for GIST treatment.
  • The company's focus on addressing unmet medical needs in oncology provides a competitive advantage in a crowded pharmaceutical landscape.
  • With a solid pipeline and strategic partnerships, Deciphera is well-positioned for future growth, aiming for over $1 billion in peak global revenue for QINLOCK and Vimseltinib.
  • The recent acquisition by Ono Pharmaceutical validates Deciphera's value and potential, potentially accelerating its global expansion and research capabilities.
  • Challenges remain in navigating regulatory hurdles and intense competition, but Deciphera's specialized focus and innovative platform provide a strong foundation for continued success.

FAQs

  1. What is Deciphera Pharmaceuticals' main focus in drug development? Deciphera specializes in developing kinase inhibitors for cancer treatment, with a particular focus on gastrointestinal stromal tumors (GIST) and other solid tumors.

  2. How has QINLOCK impacted Deciphera's market position? QINLOCK, Deciphera's treatment for fourth-line GIST, has significantly boosted the company's market position and revenue, driving its transition from a research-focused entity to a commercial-stage biopharmaceutical company.

  3. What are the key strengths of Deciphera in the competitive pharmaceutical landscape? Deciphera's strengths include its innovative switch-control kinase inhibitor platform, focus on unmet medical needs in oncology, and experienced leadership team.

  4. How is Deciphera positioned for future growth? With a strong pipeline, strategic partnerships, and a focus on expanding indications for existing drugs, Deciphera is well-positioned for future growth in the oncology market.

  5. What impact has the acquisition by Ono Pharmaceutical had on Deciphera? The $2.4 billion acquisition by Ono Pharmaceutical has provided Deciphera with additional resources and potential for expanded global reach, validating the company's value and growth potential in the pharmaceutical industry.

Sources cited:

  1. https://www.stocktitan.net/news/DCPH/
  2. https://canvasbusinessmodel.com/products/deciphera-pharmaceuticals-swot-analysis
  3. https://www.slidegenius.com/cm-faq-question/what-makes-deciphera-pharmaceuticals-presentation-design-effective-in-communicating-key-insights
  4. https://www.investing.com/news/stock-market-news/earnings-call-deciphera-reports-strong-qinlock-growth-eyes-1b-peak-revenue-93CH-3294612
  5. https://investors.deciphera.com/static-files/14c6b878-b39c-43e3-ba04-85c352b71565
  6. https://markets.businessinsider.com/news/stocks/deep-dive-into-deciphera-pharmaceuticals-stock-analyst-perspectives-5-ratings-1033306549
Last updated: 2025-02-15

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.